Alkem Laboratories Acquires Rights Shares from Wholly Owned Subsidiary
Alkem Laboratories Limited has announced the acquisition of 79,36,50,794 equity shares from its wholly owned subsidiary, Alkem Medtech Private Limited. The transaction, conducted on a rights basis, was completed with the allotment of shares on July 15, 2026.The acquisition was executed at an issue price of Rs. 13.86 per equity share, amounting to a total consideration of Rs. 11,00,00,00,005.
Strategic Purpose and Scope
The acquisition is intended to facilitate the purchase of between 51% and 55% of the total issued equity share capital of M/s. Occlutech Holding AG. The transaction was structured as a cash consideration. The company confirmed that this specific acquisition does not fall within the purview of related party transactions.Alkem Medtech Private Limited, which operates in the medical device segment specifically focusing on cardiovascular and orthopedic fields, serves as the vehicle for this acquisition. The entity was incorporated on March 27, 2024.
Financial Performance of Alkem Medtech
The following table provides a summary of the operational scale and turnover for Alkem Medtech Private Limited:| Financial Year | Turnover (INR) |
|---|---|
| FY 2025-2026 | 15.13 crores |
| FY 2024-2025 | NIL |
Transaction Details
The details of the share allotment and the entity involved are outlined below:| Particulars | Details |
|---|---|
| Entity Name | Alkem Medtech Private Limited |
| Shares Acquired | 79,36,50,794 equity shares |
| Issue Price per Share | Rs. 13.86 |
| Total Consideration | Rs. 11,00,00,00,005 |
| Allotment Date | July 15, 2026 |
| Industry | Medical Device |
ALKEM Stock Price Movement
Alkem Laboratories Limited shares edged higher today to settle at ₹5,704.00, climbing 0.80% during post-market activity. The stock saw a total trading volume of 67,604 shares as it maintained a steady trajectory throughout the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.